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that HV-CV1 and its closest homologue, an ssDNA circular 
virus of unknown taxon discovered in an Antarctic shelf 
pond, are distantly related to other CRESS-DNA viruses 
(online Technical Appendix Figure 2). HV-GcV2 and HV-
CV1 displayed no capsid protein similarity between them 
or with any other virus, as determined by blastp. Annota-
tion of the HV-CV1 capsid gene required use of HHBlits 
(https://toolkit.tuebingen.mpg.de/hhblits), a more sensitive 
algorithm (E-value 1.2E-06, probability of 97.2%).
PCR confirmed the absence of HV-GcV1 in PF2 and 
HV-GcV2 and HV-CV1 in PF1, suggesting multiple infec-
tions before each pericarditis event or a rapid fluctuation 
in the load of all 3 persisting viruses. An additional blastx 
search on 53 other virus metagenomes sequenced from 
pericardial fluids after pericarditis events failed to retrieve 
these sequences. To exclude the possibility of sample con-
tamination during procedures, we simultaneously treated a 
sample with the same reagents and kits used for PF1 and 
PF2 and surveyed it by PCR; results were negative. All 
metagenomes are publically available in the METAVIR 
(http://metavir-meb.univ-bpclermont.fr) directory under 
the pericardial fluids heading.
No relationship between these viruses and pericarditis 
was established. However, the fact that some CRESS-DNA 
viruses are animal pathogens (10) and the growing number of 
GcVs found in human samples in pathologic contexts (6,7) 
indicate that the viral genomes described here might repli-
cate in human cells, possibly as opportunistic pathogens (8). 
On the other hand, although diagnostic tests ruled out fungal 
or bacterial infections, we should still consider the possibil-
ity that these viruses infect other uncharacterized organisms. 
The genomes described here will assist further studies of the 
prevalence of these viruses in human populations.
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To the Editor: Japanese encephalitis (JE) is caused 
by a virus transmitted by Culex tritaeniorhynchus mos-
quitoes. JE was the major public health concern in South 
Korea until the late 1960s, with several thousand cases 
reported annually. The national vaccination program with 
the inactivated mouse brain–derived Nakayama strain was 
initiated in 1983 and targeted children <15 years of age. 
During 1983–2000, annual booster vaccinations were giv-
en to children <15 years of age, but in 2000, the booster 
schedule was changed to 2 doses (1 dose each) for children 
6 and 12 years of age. The live attenuated JE vaccine SA 
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14-14-2 was introduced in 2002 and included in the na-
tional immunization program in 2014. After introduction 
of the mandatory immunization program, JE was nearly 
eliminated; during most of the past 3 decades, <0.02 cases 
per 100,000 population have been reported annually (1). 
However, since 2010, JE has reemerged in South Korea. 
We describe epidemiologic data for JE, focusing on the 
recent increase in number of cases in South Korea. We 
accessed demographic information from the disease web 
statistics system provided by the Korea Centers for Disease 
Control and Prevention (2). Our study was exempted from 
review by the Institutional Review Board at Seoul National 
University Hospital (E-1602-053-739).
During 2010–2015, South Korea reported 129 JE cases 
(2). JE was diagnosed on the basis of clinical signs and 
symptoms and laboratory examination that showed either 
the presence of JE virus (JEV)–specific IgM in serum or 
cerebrospinal fluid samples or identification of a >4-fold 
increase in neutralizing antibody titers between the acute 
and convalescent stages. Laboratory procedures were 
conducted by the Korea Centers for Disease Control and 
Prevention, as described (3). Clinical features suggesting 
JEV infection were acute encephalitis syndrome (defined 
as altered consciousness with fever or seizures) and focal 
neurologic deficits. Reports excluded clinically suspected 
but serologically unconfirmed cases. Among the 129 con-
firmed cases, only 1 (0.78%) case-patient had documented 
evidence of JEV vaccination. Domestic or international 
travel history was evident in 18 (14.0%) case-patients; 16 
(12.4%) were found to live in proximity to a pigsty; and 8 
(6.2%) were foreign-born residents.
Annual incidences of JE have increased markedly 
since 2010, except for 2011, when only 3 cases were re-
ported (Figure, panel A). Incidence was highest during 
2015, when 40 cases were reported. A total of 19 patients 
died during 2010–2014 (overall case-fatality rate 21.3%), 
whereas during the previous 25 years (1985–2009), only 5 
deaths were attributable to JE (4). 
Median age of the 129 patients with JE was 53 years 
(interquartile range 46.5–62.0). Most (73 [56.6%]) patients 
were male; 56 (43.4%) were female. On average, affected 
female patients were older than male patients (mean 56.6 
± 16.3 years vs. 51.4 ± 12.8 years; p = 0.017 by Mann-
Whitney U test). When patients were stratified by age, 
those 50–59 years of age (37.2%) were the most affected 
group, followed by those 40–49 years of age (24%). Pa-
tients <19 years of age accounted for only 3.1% of cases 
(Figure, panel B). Analysis of the monthly incidence of 
JE revealed a distinctive summer peak; 109 (84.5%) cases 
occurred during August–October, suggesting a temporal 
association with activity of mosquito vectors (5). Analy-
sis of geographic distribution showed that 58 (45%) cas-
es originated in Seoul, the capital of South Korea, or in 
Gyeonggi Province, the area surrounding Seoul (online 
Technical Appendix Figure, http://wwwnc.cdc.gov/EID/
article/22/10/16-0288-Techapp.pdf).
Our findings indicated that reemerging JE predomi-
nantly affects unvaccinated adults >40 years of age. Shifts 
in age distribution toward older groups after initiation of 
vaccination programs were also evident in Japan and Tai-
wan (6,7). Many researchers believe that prolonged peri-
ods with near elimination of JE over the past 3 decades 
and an unvaccinated adult population have contributed 
to older adults’ high vulnerability to JE. However, recent 
JEV seroprevalence data showed that 98.1% of persons 
in high-risk age groups had neutralizing antibodies, with 
no differences appearing among age groups (8). Although 
those findings conflict with the assumption that lack of 
vaccination among older adults contributes to vulnerabil-
ity to infection, high seroprevalences could be explained 
by natural infection resulting from the large epidemics of 
the 1950s and 1960s.
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Figure. Reemergence of Japanese encephalitis in South Korea. A) Number of cases and deaths caused by Japanese encephalitis by 
year, 1990–2015. Number of deaths for 2015 is not shown because final data were unavailable. B) Number of cases and incidence of 
Japanese encephalitis by age group, 2010–2015. Population data for the denominator originated from the future population projection 
data of the Korea Statistical Information Service through 1992 and from the mid-year population data from the resident registration 
system as of 1993. All disease data shown in the figure were provided by the Korea Centers for Disease Control and Prevention, 
Infectious Disease Statistics System (http://is.cdc.go.kr/dstat/index.jsp).
Our study has several limitations. For example, infor-
mation on clinical features and outcomes of patients, ex-
cept for death, was unavailable, and we could not deter-
mine prognostic factors for recent JE cases. Because details 
of each patient’s travel history was not identified, we could 
not clearly understand the mechanism of JEV transmission. 
In addition, we do not explore the possible cause of JE re-
emergence. Moreover, although JE incidence was detected 
by the national surveillance system, incidence might be un-
derestimated because the database identified only serologi-
cally confirmed cases.
JE vaccination is presumed to have failed to induce 
lifelong immunity so that older age groups become sus-
ceptible again. Further research is warranted to determine 
the long-term protection against JEV after primary vacci-
nation. Moreover, future studies should address the need 
for booster vaccination for adults to maintain immunity 
against JEV.
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To the Editor: Enterovirus A71 (EV-A71) strains 
circulate worldwide, and numerous outbreaks have been 
reported from Asia, Australia, Europe, and America (1). 
Symptomatic infections range from mild febrile illness or 
characteristic diseases such as hand, foot and mouth dis-
ease to severe neurologic disorders such as meningitis/
encephalitis and acute flaccid paralysis. EV-A71 infections 
are usually asymptomatic and self-limiting but can also 
result in life-threatening complications such as pulmonary 
edema and cause death, predominantly in children <5 years 
of age. On the basis of viral protein 1 (VP1) sequences, 3 
genogroups (A, B, C), including different subgenogroups 
(B0–B5, C1–C5), have been defined (2,3). Additional geno-
groups (D, E, F, G) have been proposed (4,5). In Europe, 
C1 and C2 strains have circulated predominantly within the 
past 2 decades, and recent introduction of C4 strains has 
been reported (6,7). Within subgenogroup C1, a lineage is 
replaced by the subsequent lineage over time (8). 
National enterovirus surveillance (EVSurv) in Ger-
many monitors polio-free status by testing fecal or cere-
brospinal fluid (CSF) samples from hospitalized patients 
with suspected meningitis/encephalitis or acute flaccid pa-
ralysis. Enterovirus typing, using molecular and virologic 
methods, is performed within a laboratory network for 
enterovirus diagnostics. Since 2006, ≈2,500 samples have 
been tested annually; 25%–30% were enterovirus positive. 
Of the typed strains, 0.8%–12.7% were identified as EV-
A71 (2006, 0.8%; 2007, 6.8%; 2008, 0.9%; 2009, 3.4%; 
2010, 12.7%; 2011, 2.3%; 2012, 2.8%; 2013, 8.6%; 2014, 
2.7%), indicating peaks with increased EV-A71 detection 
rates. Molecular characterization based on the VP1 region 
of a subset of EV-A71–positive samples revealed that C2 
was the predominant subgenogroup in Germany from 2006 
to 2014. Subgenogroups B5, C1, and C4 have also been 
identified, but less frequently (online Technical Appendix 
Table 3, http://wwwnc.cdc.gov/EID/article/22/10/16-0357-
Techapp1.pdf). 
In 2015, a total of 419 samples tested enterovirus 
positive within EVSurv. Of these, 43 fecal specimens and 
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